Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 4 × Carcinoma, Hepatocellular × contrast agent BR1 × Clear all

Phase

Phase 4 1 Phase 3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 1

Interventions

Sorafenib 8 gadolinium ethoxybenzyl DTPA 4 Hepatectomy 4 lenvatinib 3 Sufentanil 3 Ribavirin 3 Propranolol 3 sofosbuvir-velpatasvir drug combination 2 peginterferon alfa-2a 2 gadoterate meglumine 2 entecavir 2 Thrombectomy 2 Tenofovir 2 Sevoflurane 2 Lamivudine 2 Esketamine 2 Chemoembolization, Therapeutic 2 xihuang 1 stronger neominophagen C 1 ledipasvir 1 huaier 1 gadoteridol 1 gadodiamide 1 gadobutrol 1 gadobenic acid 1 flurbiprofen axetil 1 fish oil triglycerides 1 contrast agent BR1 1 chlorhexidine gluconate 1 cantharidin methylimide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04569799 2023-11-02

TACE

Milton S. Hershey Medical Center

Phase 4 Completed

26 enrolled 10 charts

Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon ⚡